Renal cell carcinomas (RCCs) were more apt to be reported as unspecified histology in community programs than in other program types, researchers concluded after conducting an analysis involving nearly 300,000 RCCs. Participants were from the National Cancer Database and diagnosed with RCC between 1998 and 2014. Investigators examined proportions of RCC with unspecified vs specific histologies, and assessed the impact facility type had on these proportions. Among the results:
- Over the course of the study, the portion of histologically unspecified RCC decreased dramatically in all facility types.
- It decreased from 86% to 28% in community programs (the smallest drop).
- It went from 85% to 10% in NCI-designated centers (the largest decrease).
- Compared with community programs, RCCs were 21% less likely to be reported as unspecified histology in comprehensive community programs.
- They were 32% less likely to be reported as such in both integrated network and academic programs, and 63% less likely in NCI-designated programs.
- Proportions of papillary, clear cell, and chromophobe RCC cases increased.
Gansler T, Fedewa S, Amin M, Lin C, Jemal A. Trends in reporting histological subtyping of renal cell carcinoma: Association with cancer center type. [Published online ahead of print January 12, 2018]. Hum Pathol. doi:10.1016/j.humpath.2018.01.010.
This Week's Must Reads
Flat pricing of ibrutinib , Sales revenues at the potential expense of patient safety https://cancerletter.com/articles/20180413_5/
Most oncologists discuss medical marijuana with patients, Braun I et al. J Clin Oncol. 2018 May 10. doi: 10.1200/JCO.2017.76.1221.
$800M cut proposed for Centers for Medicare & Medicaid Innovation, Proposed rescission of budget authority https://www.whitehouse.gov/wp-content/uploads/2018/05/POTUS-Rescission-Transmittal-Package-5.8.2018.pdf
Medicare Beneficiary Identifiers required for billing by 2019, New Medicare cards https://www.cms.gov/medicare/new-medicare-card/nmc-home.html
Trump administration unveils drug pricing initiative, American Patients First https://www.hhs.gov/sites/default/files/AmericanPatientsFirst.pdf
Must Reads in Renal Cell Carcinoma
miRNAs are biomarkers for RCC prognosis, Pan X et al. Biomedicine and Pharmacotherapy 102: 2018; 718-27. https://doi.org/10.1016/j.biopha.2018.03.072
Pseudocapsule status predicts RCC prognosis, Xi W et al. The Journal of Urology 199: 2018; 915-20. https://doi.org/10.1016/j.juro.2017.10.043
New model uses histologic subtypes to predict RCC prognosis, Leibovich B et al. European Urology 73; 2018: 772-80. https://doi.org/10.1016/j.eururo.2018.01.005
Histologic similarities in clear cell papillary RCC and tuberous sclerosis, Williamson S et al. Human Pathology 75; 2018: 10-15 https://doi.org/10.1016/j.humpath.2017.11.013
IMDC risk group classification predicts sunitinib response, Rini B et al. Clinical Genitourinary Cancer; published online May 4, 2018 https://doi.org/10.1016/j.clgc.2018.04.005